샘플 요청 목록

 카트 문의
시장보고서
상품코드
1783994

폐선암 치료 시장

Lung Adenocarcinoma Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 291 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

폐선암 치료 세계 시장은 2030년까지 102억 달러에 달할 전망

2024년에 59억 달러로 추정되는 폐선암 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 9.6%로 성장하여 2030년에는 102억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 화학요법은 CAGR 7.7%를 기록하며 분석 기간 종료시에는 35억 달러에 달할 것으로 예측됩니다. 표적요법 분야의 성장률은 분석 기간 동안 CAGR 11.4%로 추정됩니다.

미국 시장은 16억 달러로 추정, 중국은 CAGR 12.8%로 성장 예측

미국의 폐선암 치료 시장은 2024년에 16억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2024년부터 2030년 분석 기간 동안 CAGR 12.8%로 성장하여 2030년까지 20억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 7.1%와 8.3%로 예측됩니다. 유럽에서는 독일이 CAGR 약 7.5%로 성장할 것으로 예측됩니다.

세계의 폐선암 치료 시장 - 주요 동향과 촉진요인 정리

폐선암이 암 분야에서 두각을 나타내는 이유는 무엇일까?

비소세포폐암(NSCLC)의 아형인 폐선암은 폐암 발생의 약 40%를 차지하며 폐암 중 가장 발병률이 높은 질환입니다. 발병률의 증가는 대기오염, 흡연 등의 환경적 노출과 특정 집단의 유전적 소인과 밀접한 관련이 있습니다. 종양학 분야에서 이 질병이 두드러지는 이유는 복잡한 분자 프로파일로 인해 표적 치료의 혁신에 박차를 가하고 있기 때문입니다. EGFR 돌연변이에서 ALK 및 ROS1 재조합에 이르기까지, 발암 동인의 식별은 치료 전략을 재정의하고 제약 연구를 보다 개인화된 바이오마커 중심의 치료 요법으로 발전시키고 있습니다. 기존 화학요법과는 달리, 이러한 치료법은 전신 부작용이 적고 효능이 높으며, 초기 및 진행 단계 모두에서 환자 치료의 패러다임을 바꾸고 있습니다.

새로운 치료법은 표준 치료를 재구성할 것인가?

면역치료와 차세대 표적 치료제의 도입으로 폐선암의 치료 환경이 급변하고 있습니다. 펨브롤리주맙, 니볼루맙과 같은 면역관문억제제는 특히 1차 치료제로 사용되었을 때 PD-L1 고발현 환자에서 유의한 생존 혜택을 보였습니다. 한편, EGFR 및 기타 돌연변이를 표적으로 하는 3세대 티로신 키나아제 억제제(TKI)의 등장은 특히 내성 및 전이성 사례에서 치료 성적을 더욱 개선했습니다. 면역항암제와 화학요법제 또는 TKI를 병용하는 병용요법은 활발히 연구되고 있으며, 임상시험에서 유망한 치료법으로 평가받고 있습니다. 또한, 이중특이성항체, 항체약물접합체(ADC), mRNA 기반 접근법도 개발 중으로, 종양 진행과 약물 내성에 대한 무기가 확대되고 있습니다. 이러한 기술 혁신은 치료 프로토콜에서 면역학과 유전체학의 융합이 진행되고 있음을 반영합니다.

진단의 획기적인 발전은 어떻게 치료의 정확도를 높이고 있는가?

진단의 발전은 폐선암의 치료 경로를 최적화하는 데 매우 중요한 역할을 하고 있습니다. 액체 생검, 차세대 염기서열 분석(NGS), 멀티플렉스 분자 프로파일링은 임상적 의사결정에 필수적인 도구로 부상하고 있습니다. 이러한 기술은 최소한의 생물학적 물질에서 실용적인 돌연변이를 검출할 수 있으며, 질병의 진행과 치료 효과를 실시간으로 모니터링할 수 있게 해줍니다. 중요한 것은 AI 기반 진단 플랫폼의 통합으로 병리학적 분석의 속도와 정확도가 향상되고, 치료 시작까지의 시간이 개선되고 있다는 점입니다. 정밀의료가 표준으로 자리 잡으면서 전 세계 규제 당국도 이러한 변화에 발맞춰 동반진단 약품의 승인 절차를 간소화하고 보다 폭넓은 접근성을 보장하고 있습니다. 이러한 추세는 예후를 개선할 뿐만 아니라 보다 적응적이고 비용 효율적인 치료 모델을 도입할 수 있게 합니다.

폐선암 치료 시장의 성장 원동력은?

폐선암 치료 시장의 성장은 기술 혁신, 임상 진료의 변화, 환자층의 진화에 기반한 여러 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 분자진단 및 개별화 치료 접근법의 채택이 증가하고 있으며, 이로 인해 의약품 개발 및 환자 계층화가 가속화되고 있다는 점입니다. 또 하나는 면역관문억제제 및 표적 치료제의 적응증 확대로 대상 환자층이 크게 확대되고 있다는 점입니다. AI와 머신러닝의 발전은 Drug Discovery와 임상시험 설계를 간소화하고, 새로운 치료제의 시장 출시 시간을 단축하고 있습니다. 또한, 폐암에 취약한 전 세계 노인 인구의 증가와 신흥국에서의 인식 개선은 조기 진단 및 치료율을 높이고 있습니다. 또한, 제약사, 바이오텍 기업, 학계의 협력 관계가 강화되면서 병용요법 및 차세대 생물학적 제제의 신속한 개발이 촉진되고 있습니다. 마지막으로, 주요 시장에서의 상환 지원과 의료 정책 개혁은 환자들의 프리미엄 치료 접근성을 향상시켜 시장 확대를 더욱 촉진하고 있습니다.

부문

치료(화학요법, 표적요법, 면역요법, 방사선 치료, 기타), 최종사용 채널(병원, 전문 클리닉, 기타)

조사 대상 기업 사례

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • BioNTech SE
  • Biotheus Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.(a member of the Roche Group)
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.11

Global Lung Adenocarcinoma Treatment Market to Reach US$10.2 Billion by 2030

The global market for Lung Adenocarcinoma Treatment estimated at US$5.9 Billion in the year 2024, is expected to reach US$10.2 Billion by 2030, growing at a CAGR of 9.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 11.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 12.8% CAGR

The Lung Adenocarcinoma Treatment market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.0 Billion by the year 2030 trailing a CAGR of 12.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Lung Adenocarcinoma Treatment Market - Key Trends & Drivers Summarized

What Makes Lung Adenocarcinoma Stand Out in the Oncology Landscape?

Lung adenocarcinoma, a subtype of non-small cell lung cancer (NSCLC), accounts for nearly 40% of all lung cancer cases, making it the most prevalent form of the disease. Its increasing incidence is largely linked to environmental exposures, including air pollution and smoking, as well as genetic predispositions in certain populations. What sets it apart in the oncology spectrum is its complex molecular profile, which has spurred a wave of targeted therapy innovations. From EGFR mutations to ALK and ROS1 rearrangements, the identification of oncogenic drivers has redefined therapeutic strategies, pushing pharmaceutical research toward more personalized, biomarker-driven treatment regimens. In contrast to traditional chemotherapy, these therapies offer higher efficacy with fewer systemic side effects, transforming the patient care paradigm in both early-stage and advanced settings.

Are Emerging Therapies Reshaping the Standard of Care?

The therapeutic landscape for lung adenocarcinoma has undergone a radical shift with the introduction of immunotherapies and next-generation targeted treatments. Immune checkpoint inhibitors such as pembrolizumab and nivolumab have demonstrated significant survival benefits in patients with high PD-L1 expression, especially when used as first-line treatments. Meanwhile, the advent of third-generation tyrosine kinase inhibitors (TKIs) targeting EGFR and other mutations has further improved outcomes, particularly in resistant or metastatic cases. Combination therapies-pairing immune agents with chemotherapeutics or TKIs-are being actively explored and show promise in clinical trials. Additionally, bispecific antibodies, antibody-drug conjugates (ADCs), and mRNA-based approaches are in development, expanding the arsenal against tumor progression and drug resistance. These innovations reflect a growing convergence of immunology and genomics in treatment protocols.

How Are Diagnostic Breakthroughs Fueling Therapeutic Precision?

Diagnostic advancements are playing a pivotal role in optimizing treatment pathways for lung adenocarcinoma. Liquid biopsy, next-generation sequencing (NGS), and multiplex molecular profiling have emerged as indispensable tools in clinical decision-making. These technologies allow for the detection of actionable mutations from minimal biological material, enabling real-time monitoring of disease progression and therapeutic efficacy. Importantly, the integration of AI-driven diagnostic platforms is enhancing the speed and accuracy of pathology analysis, improving turnaround times for treatment initiation. As precision medicine becomes the norm, regulatory bodies worldwide are also aligning with this shift-streamlining the approval process for companion diagnostics and ensuring broader access. These trends not only improve prognosis but also enable the implementation of more adaptive and cost-effective treatment models.

What Is Driving the Growth Momentum in the Lung Adenocarcinoma Treatment Market?

The growth in the lung adenocarcinoma treatment market is driven by several factors rooted in technological innovation, changing clinical practices, and evolving patient demographics. One major driver is the increasing adoption of molecular diagnostics and personalized treatment approaches, which is accelerating drug development and patient stratification. Another is the expansion of indications for immune checkpoint inhibitors and targeted therapies, which has significantly widened the eligible patient pool. Advances in AI and machine learning are streamlining drug discovery and clinical trial design, reducing time-to-market for novel treatments. Additionally, a rising global geriatric population-more susceptible to lung cancers-and increased awareness in emerging economies are boosting early diagnosis and treatment rates. Growing collaborations between pharmaceutical companies, biotech firms, and academic institutions are also facilitating the rapid development of combination therapies and next-generation biologics. Finally, reimbursement support and healthcare policy reforms in key markets are enabling better patient access to premium therapies, further propelling market expansion.

SCOPE OF STUDY:

The report analyzes the Lung Adenocarcinoma Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Others); End-Use Channel (Hospitals, Specialty Clinics, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • BioNTech SE
  • Biotheus Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • CStone Pharmaceuticals
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc. (a member of the Roche Group)
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Lung Adenocarcinoma Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Lung Adenocarcinoma Globally Spurs Demand for Novel Therapeutic Options
    • Increasing Preference for Targeted Therapies Drives Adoption of Molecularly Guided Treatment Regimens
    • Growing Utilization of Companion Diagnostics Strengthens Business Case for Personalized Medicine
    • Advancements in Liquid Biopsy Technology Expand Addressable Market Opportunity for Early Detection and Monitoring
    • Accelerated FDA Approvals of Novel Oncology Drugs Propel Growth in Precision Treatment Portfolios
    • Increasing Integration of Artificial Intelligence in Oncology Workflows Drives Operational Efficiency and Treatment Accuracy
    • Expansion of Biomarker Testing Infrastructure Generates Demand for Genotype-Driven Therapy Selection
    • Widespread Adoption of Immunotherapy Throws the Spotlight on Checkpoint Inhibitors and Novel Combinations
    • Rise in Awareness and Screening Programs in Emerging Markets Opens New Growth Corridors for Treatment Providers
    • Growing Investments in Oncology R&D Sustain Innovation-Led Growth in Lung Cancer Treatment
    • Increasing Multidisciplinary Approaches in Cancer Care Accelerate Demand for Integrated Treatment Models
    • High Unmet Clinical Need in Refractory and Advanced-Stage Cases Strengthens Market for Next-Generation Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Lung Adenocarcinoma Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Lung Adenocarcinoma Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Lung Adenocarcinoma Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Lung Adenocarcinoma Treatment by Treatment - Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Lung Adenocarcinoma Treatment by Treatment - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Other Treatments for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Lung Adenocarcinoma Treatment by End-Use Channel - Hospitals, Specialty Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Lung Adenocarcinoma Treatment by End-Use Channel - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제